Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 15:5:12.
doi: 10.1186/s40364-017-0093-8. eCollection 2017.

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Laurence P Diggs  1 , Eddy C Hsueh  1
Affiliations
Review

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Laurence P Diggs et al. Biomark Res. .

Abstract

We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response stratification and not patient selection. Further improvement in assay development is needed to utilize this type of assay in identification of ideal patient population for this therapy.

Keywords: Metastatic melanoma; Non-Small-Cell Lung Cancer; PD-1/PD-L1 inhibitors; PD-L1 immunohistochemistry assays.

PubMed Disclaimer

References

    1. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. doi: 10.1038/nature13954. - DOI - PMC - PubMed
    1. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965–70. doi: 10.1158/1055-9965.EPI-14-0654. - DOI - PubMed
    1. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56. doi: 10.1158/1535-7163.MCT-14-0983. - DOI - PubMed
    1. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 2014;25(12):2433–42. doi: 10.1093/annonc/mdu452. - DOI - PubMed
    1. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21(9):1065–77. doi: 10.1093/intimm/dxp072. - DOI - PMC - PubMed

LinkOut - more resources